RG 7882

Drug Profile

RG 7882

Alternative Names: D-4064A; DMUC 4064A; RG7882

Latest Information Update: 02 Aug 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Genentech
  • Class Antineoplastics; Drug conjugates; Immunoconjugates; Immunotoxins; Monoclonal antibodies
  • Mechanism of Action Membrane protein inhibitors; Tumour-associated carbohydrate antigen inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Ovarian cancer; Pancreatic cancer

Most Recent Events

  • 26 Jul 2018 Discontinued - Phase-I for Ovarian cancer (Second-line therapy or greater) in USA (IV) (Roche pipeline, July 2018)
  • 26 Jul 2018 Discontinued - Phase-I for Pancreatic cancer (Inoperable/Unresectable, Late-stage disease, Metastatic disease, Recurrent) in USA (IV) (Roche pipeline, July 2018)
  • 18 Jun 2018 Genentech completes a phase I trial in Pancreatic cancer (Inoperable/Unresectable, Late-stage disease, Metastatic disease, Recurrent) and Ovarian Cancer (Second line therapy or greater) in USA (IV) (NCT02146313)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top